16 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
19800231	92	Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.	Schering-Plough Research Institute
17300166	88	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.	University of Montpellier
10201826	24	Synthesis of oxytocin antagonists containing conformationally constrained amino acids in position 2.	Albert Szent-Gy£Rgyi Medical University
21353540	55	Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.	Msd
20550119	96	Oral oxytocin antagonists.	Drugmoldesign
20719508	26	Identification and optimization of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V3 (V1b) receptor antagonists.	Ligand Pharmaceuticals
	4	Vasopressin trisulphide: synthesis, NMR study and affinity studies with V1 and V2 subtypes receptors	TBA
14695824	68	Synthesis and structure-activity relationships of 5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepine derivatives: novel arginine vasopressin antagonists.	Central Pharmaceutical Research Institute
12502367	17	New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization.	Université
8258821	491	Nanomolar-affinity, non-peptide oxytocin receptor antagonists.	Merck Research Laboratories
30199637	172	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.	Umr7200 Cnrs/Universit£
2416923	40	Arginine-vasopressin analogues with high antidiuretic/vasopressor selectivity. Synthesis, biological activity, and receptor binding affinity of arginine-vasopressin analogues with substitutions in positions 1, 2, 4, 7, and 8.	TBA
2163451	45	Cyclic hexapeptide oxytocin antagonists. Potency-, selectivity-, and solubility-enhancing modifications.	Merck Sharp & Dohme Research Laboratories
1331449	268	Orally active, nonpeptide oxytocin antagonists.	Merck Research Laboratories